Ipca Laboratories Ltd
Ipca Laboratories Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #36 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Domestic business expected to grow at 10-12% annually, driven by branded formulations, CNS, neurology, and cardiology segments. - Export promotional branded business anticipated to grow steadily at 10-12% over the long term. - Generic business growth expected at 10-12%, with faster growth in Europe and U.S. Unichem U.S.
From Ipca Laboratories Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Domestic business expected to grow at 10-12% annually, driven by branded formulations, CNS, neurology, and cardiology segments.
- Export promotional branded business anticipated to grow steadily at 10-12% over the long term.
- Generic business growth expected at 10-12%, with faster growth in Europe and U.S. markets.
- U.S. market (Unichem business) projected to grow 8-10% annually over the next 2-3 years after regaining market share.
- Ipca U.S. business plans to commercialize 4-5 new molecules annually; 7-8 commercialized in last years, with growth from backward-integrated molecules.
- API business to have a slightly lower growth than formulations but improved in last quarters.
2 more points from Ipca Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Ipca Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No major expansion plans currently, except for a solar project focused on using more green energy.
- The solar project has a capital expenditure outlook of approximately INR 50 crores.
- No other significant capital expenditure plans announced at this time.
2 more points from Ipca Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Ipca Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Ipca Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Ipca Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹2.4K Cr, net profit ₹364 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ipca Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Ipca Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ipca Laboratories Ltd Q3 FY26 results?
Domestic business expected to grow at 10-12% annually, driven by branded formulations, CNS, neurology, and cardiology segments. - Export promotional branded business anticipated to grow steadily at 10-12% over the long term. - Generic business growth expected at 10-12%, with faster growth in Europe and U.S. Unichem U.S.
What is Ipca Laboratories Ltd share price analysis?
Ipca Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 32.0 with a market cap of ₹43,997 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ipca Laboratories Ltd planning capital expenditure?
No major expansion plans currently, except for a solar project focused on using more green energy.
Keep Ipca Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.